News Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
15.04 ^USD	+0.27%		+2.04%	+12.16%

Mar. 27	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	MT
Mar. 07	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	Apr. 30	BU
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
Merrimack Receives $225 Million Milestone Payment from Ipsen	Mar. 27	BU
Merrimack Reports Full Year 2023 Financial Results	Mar. 07	BU
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 14	AQ
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Feb. 13	BU
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	Nov. 16	MT
Merrimack Reports Third Quarter 2023 Financial Results	Nov. 02	BU
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	23-09-18	CI
Insider Buy: Merrimack Pharmaceuticals	23-08-09	MT
Merrimack Reports Second Quarter 2023 Financial Results	23-08-03	BU
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Index	23-06-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Summary

Filters